CClinicalTrials.gg
Active, not recruitingNCT06813053Updated Sep 3, 2026

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

An interventional study of Decision Aid (DA) and Standard of Care (SOC) in Breast Cancer, sponsored by University of Colorado, Denver. Active, not recruiting at 3 sites in United States. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Female
01

Study summary

This is a study to assess the feasibility and acceptability of a novel decision aid (DA) in a newly diagnosed, early-stage breast cancer population. Insights gained from patient feedback and the implementation process will be used to improve the information delivered in the decision aid itself and to plan for a larger scale trial to compare the decision aid to standard of care.

Read the detailed description

This pilot study will utilize several tools and instruments to measure various aspects of of the implementation of the decision aid. 1. BREAST-Q patient-Reported Outcomes, 2. Ottawa Decision Aid Evaluation Measures, 3. Health Literacy Assessments, 4. Distress Screening Tools, 5. Web-Based Surveys, 6. Semi-Structured Interviews.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Early-Stage
  • Newly Diagnosed
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,499 studies on the registry; 315 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 89 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Adult women age 18-100
  • English speaking
  • Clinical stage 0-III breast cancer
  • Eligible for both lumpectomy and mastectomy

Exclusion criteria

Exclusion Criteria:

  • Prior surgical consultation regarding treatment options for breast cancer
  • Previous history of breast cancer
  • Requires neoadjuvant chemotherapy prior to surgical intervention
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Interventional Group

    Newly detected, early stage breast cancer patients in the treatment group will be provided an electronic copy of the DA for their reference via email.

    Other: Decision Aid (DA)

  • Placebo comparator
    Control Group

    Newly diagnosed, early stage breast cancer patients in the control group will be provided an electronic copy of an alternative educational pamphlet discussing surgical options for breast cancer.

    Other: Standard of Care (SOC)

Interventions

  • OtherDecision Aid (DA)

    Tools designed to foster shared decision-making by contextualizing the risks and benefits of treatment options around the patient's personal values, thereby allowing them to weigh personal preferences when making treatment decisions. The study team has developed a prototype DA incorporating longitudinal institutional QoL data among patients who have undergone breast cancer surgery .

  • OtherStandard of Care (SOC)

    Electronic copy of an alternative educational pamphlet discussing surgical options for breast cancer.

06

What researchers measure

Primary outcomes

  1. Assess the feasibility of prospectively providing a novel DA to early stage breast cancer patients

    Monitor the recruitment process of eligible patients. Including tracking how many patients are approached, how many participate and how effective the decision aid engages patient in the decision making process. High participation and engagement indicates a successful implementation. Compare clinician reported length of encounter between interventions as a balancing measure.

    Time frame: 1 year

  2. Evaluate how well patients receive the decision aid

    Use the validated and accepted Ottawa Decision Aid metrics to assess decision quality, decisional conflict, acceptability, and regret. Conduct semi-structured interviews to gather additional qualitative data regarding the patient experience, and use feedback to modify and improve the content and design of the Decision Aid.

    Time frame: 1 year

Secondary outcomes

  1. Maximize patient engagement with the decision aid

    Optimal timing and mode of delivery will be determined by the engagement of patients with the decision aid (DA) based on the time the DA was offered. Qualitative feedback from semi-structured interviews will provide additional context for engagement with paper versus digital copies, and engagement prior to versus after meeting with the surgeon.

    Time frame: 1 year

  2. Obtain pilot data for a large scale randomized controlled trial comparing use of the decision aid to standard of care in early-stage breast cancer patients.

    Patient-reported Decision Aid Acceptability, Decision Quality, Self Efficacy, Decision Conflict, and Decision Regret (from the Ottawa Decision Aid Measures) as well as Patient-reported distress will be compared between intervention groups. Differences in these key outcomes will be used to perform a power analysis to determine optimal enrollment size for a large scale multicenter randomized controlled trial.

    Time frame: 1 year

07

Study locations

3 sites
  • Universtiy of Colorado Hospital
    Aurora, Colorado 80045, United States
  • UCHealth Cherry Creek Medical Center
    Denver, Colorado 80206, United States
  • UCHealth Highlands Ranch Hospital
    Highlands Ranch, Colorado 80129, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06813053
Lead sponsor
University of Colorado, Denver
Collaborators
Association of Academic Surgery
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Jul 21, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Sarah Tevis, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion